Surmodics Price to Free Cash Flow Ratio 2010-2024 | SRDX

Surmodics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Surmodics Price to Free Cash Flow Ratio 2010-2024 | SRDX

Surmodics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$200B
Stryker (SYK)$141B
Boston Scientific (BSX)$128B
Medtronic (MDT)$113B
EssilorLuxottica (ESLOY)$112.7B
Lonza Group Ag (LZAGY)$45.3B
Haleon (HLN)$43.5B
GE HealthCare Technologies (GEHC)$40.4B
ResMed (RMD)$36.5B
Terumo (TRUMY)$30.3B
Koninklijke Philips (PHG)$25.9B
Zimmer Biomet Holdings (ZBH)$21.6B
Baxter (BAX)$18.4B
Insulet (PODD)$17.2B
Smith & Nephew SNATS (SNN)$10.8B
Bio-Rad Laboratories (BIO)$10.4B
BellRing Brands (BRBR)$8.9B
Demant (WILYY)$8.4B
Lantheus Holdings (LNTH)$6.1B
Haemonetics (HAE)$4.4B
ICU Medical (ICUI)$4.4B
TG Therapeutics (TGTX)$4.3B
Prestige Consumer Healthcare (PBH)$4B
Envista Holdings (NVST)$3.7B
Perrigo (PRGO)$3.7B
Neogen (NEOG)$3.4B
Agios Pharmaceuticals (AGIO)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.6B